济民药业,关爱无限 www.pidrug.com
香港济民药业微信二维码
198 9654 1773
当前位置:首页 > 药品资讯 > 精神科 > 氢溴酸右美沙芬dextromethorphan

氢溴酸右美沙芬dextromethorphan

[ 人气:112 | 日期: 2020-08-04 | 返回 | 打印 ]
氢溴酸右美沙芬dextromethorphan
药品名称:氢溴酸右美沙芬dextromethorphan
药品别名:安咳锭、镇咳锭、治咳锭、去咳锭、可扶康锭、咳德锭
英 文 名:dextromethorphan
药品价格:$ 美国市场售价 8.9 美元
研发公司:
适 用 症:主要用于干咳,适用于感冒、急性或慢性支气管炎、支气管哮喘、咽喉炎、肺结核以及其他上呼吸道感染时的咳嗽。
型号规格:本品为胶囊、片剂、口服液等多种规格。
药品详情:

【氢溴酸右美沙芬dextromethorphan 简述】
 
    本品又名安咳锭、镇咳锭、治咳锭、去咳锭、可扶康锭、咳德锭等,是一种止咳类药品。

氢溴酸右美沙芬dextromethorphan_香港济民药业
 
【氢溴酸右美沙芬dextromethorphan 适应症】
 
    本品主要用于干咳,适用于感冒、急性或慢性支气管炎、支气管哮喘、咽喉炎、肺结核以及其他上呼吸道感染时的咳嗽。
 
【氢溴酸右美沙芬dextromethorphan 规格】
 
    本品为胶囊、片剂、口服液等多种规格。
 
【氢溴酸右美沙芬dextromethorphan 服用方法】
 
    患者应完全遵循主治医师或说明书上的指示服用,不可服用超过每日允许的推荐量。
 
【氢溴酸右美沙芬dextromethorphan 注意事项】
 
    1.与单胺氧化酶抑制剂并用时,可致高烧、昏迷,甚至死亡。
 
    2.不得与抗抑郁药并用。
 
    3.不宜与乙醇及其他中枢神经系统抑制药物并用,因可增强对中枢的抑制作用。
 
【氢溴酸右美沙芬dextromethorphan 不良反应】
 
    偶有头晕、轻度嗜睡、口干、便秘等副作用,孕妇及痰多病人慎用,妊娠3个月内妇女及有精神病史者禁用。勿过量服用,24小时内应不超过8片(120mg)。

 
Dextromethorphan

 
    Dextromethorphan (DXM or DM) is a medication most often used as a cough suppressant in over-the-counter cold and coughmedicines. It is sold in syrup, tablet, spray, and lozenge forms. 
 
    It is in the morphinan class of medications with sedative, dissociative, and stimulant properties (at lower doses). In its pure form, dextromethorphan occurs as a white powder.[3] 
 
    DXM is also used recreationally. When exceeding approved dosages, dextromethorphan acts as a dissociative anesthetic. It has multiple mechanisms of action, including actions as a nonselective serotonin reuptake inhibitor[4] and a sigma-1 receptor agonist.[5][6] DXM and its major metabolite, dextrorphan, also act as an NMDA receptor antagonist at high doses, which produces effects similar to, yet distinct from, the dissociative states created by other dissociative anesthetics such as ketamine and phencyclidine.
 
    It was patented in 1949 and approved for medical use in 1953.[7]
 
Medical uses
 
Cough suppression
 
    The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and common cold), as well as those resulting from inhaled particle irritants.[8] However, controlled studies have found the symptomatic effectiveness of dextromethorphan similar to placebo.[9]
 
 
Neuropsychiatric disorders
 
    In 2010, the FDA approved the combination drug dextromethorphan/quinidine for the treatment of pseudobulbar affect (uncontrollable laughing/crying). Dextromethorphan is the actual therapeutic agent in the combination; quinidinemerely serves to inhibit the enzymatic degradation of dextromethorphan and thereby increase its circulating concentrations via inhibition of CYP2D6.[10]
 
    In 2013, a randomized clinical trial was conducted at Tabriz University of Medical Sciences in Tabriz, Iran, that indicated dextromethorphan may help reduce the overall discomfort and duration of withdrawal symptoms associated with Opioid use disorder. When combined with Clonidine, dextromethorphan reduced the overall time needed for withdrawal symptoms to peak by 24 hours while also reducing the severity of the symptoms compared to Clonidine alone.[11]
 
    In 2016, the ASA released a promising study with the combination of dextromethorphan with pregabalin, acetaminophen, and naproxen which showed a decrease in postoperative pain intensity (preemptive analgesia).[12]
 
Contraindications
 
    Because dextromethorphan can trigger a histamine release (allergic reaction), atopic children, who are especially susceptible to allergic reactions, should be administered dextromethorphan only if absolutely necessary, and only under the strict supervision of a healthcare professional.[13]
 
 
Adverse effects
 
    Adverse effects of dextromethorphan in overdose at doses 3 to 10 times the recommended therapeutic dose:[17][not in citation given]
euphoria
increased energy
increased confidence
mild nausea
restlessness
insomnia
talking fast
feelings of increased strength
dilated pupils
glassy eyes
dizziness
 
    At doses 15 to 75 times the recommended therapeutic dose:[17][not in citation given]
hallucinations
dissociation
vomiting
blurred vision
double vision
bloodshot eyes
dilated pupils
sweating
fever
bruxia (teeth grinding)
hypotension
hypertension
tachycardia
shallow respiration
diarrhea
urinary retention
muscle spasms
sedation
euphoria
paresthesia
blackouts
sight loss
inability to focus eyes
skin rash
severe itchieness
 
 




注:药品如有新包装,以新包装为准。以上资讯仅供医护人员内部讨论,不作任何用药依据,具体用药指引,请咨询主治医师。

更多相关资讯:返回顶部
最新药品资讯
  • Venclyxto(维奈妥拉)联合MabThera治疗慢淋白血病,患者死亡风险降低!
  • Tagrisso(Osimertinib)在英国获批用于两种肺癌适应症的治疗
  • ziritaxestat治疗弥漫性皮肤系统性硬化症(dcSSc)2期概念验证研究成功!
  • 美国FDA批准GSK三联疗法:可同时治疗哮喘和慢阻肺
  • NBIb-1817一次性治疗帕金森病(PD)显著改善运动功能、延长ON时间
  • 口服抗生素tebipenem HBr治疗cUTI和AP关键III期临床成功,疗效不劣于ertapenem
  • 下一代选择性免疫调节剂IMU-838治疗多发性硬化症(RRMS)具有显著疗效,有良好的安全性和耐受性!
  • Fintepla(芬氟拉明)口服溶液治疗Dravet综合征相关癫痫的第三项3期研究结果:抽搐发作显著减少
  • 视神经脊髓炎谱系障碍(NMOSD)创新药Enspryng(satralizumab)获美FDA批准
  • Fasenra与标准类固醇同时治疗鼻息肉三期临床结果积极
  • Darzalex Faspro申请新适应症,治疗轻链(AL)淀粉样变性!
  • 地诺单抗(Xgeva,denosumab)治疗实体瘤骨转移疗效怎样?
  • 新药IDH1抑制剂Tibsovo治疗胆管癌效果怎么样?
  • 拜耳Nubeqa(达罗他胺)治疗非转移性去势抵抗性前列腺癌显著延长患者生存!
  • FDA对罗氏Tecentriq治疗三阴性乳腺癌研究发出警告!
  • 加码多发性硬化症!罗氏启动三项临床试验研究
  • Xeglyze说明书-价格-功效与作用-副作用
  • 赛诺菲/再生元Dupixent(达必妥®)显著延缓哮喘患者肺功能下降:疗效维持3年!
  • 默沙东止咳药gefapixant2项关键III期临床试验成功:咳嗽频率显著降低
  • Ryplazim(纤溶酶原)再次申请上市:首个先天性纤溶酶原缺乏症(C-PLGD)治疗药物!
  • 拜耳Adempas用于经PDE5i治疗反应不足的肺动脉高压(PAH)患者IV期临床成功
  • Midostaurin(米哚妥林)适应症是什么?优势在哪里?
  • 艾普利Apixaban可以在哪里买到正品?
  • 维奈妥拉/维奈托克(VENETOCLAX)怎么服用?注意事项是什么?
  • 芦可替尼Ruxolitinib治疗特应性皮炎效果好不好?
  • 巯嘌呤片(6-MP)Puri-nethol治疗急性白血病效果如何?
  • 晚期HCC患者能从Ramucirumab中获益吗?
  • 赫赛汀+拉帕替尼治疗乳腺癌效果更好
  • 欧盟批准Imfinzi(英飞凡):一线治疗广泛期小细胞肺癌(ES-SCLC)!
  • 第三代强效COMT抑制剂Ongentys(opicapone)用于治疗帕金森病(PD)的新药在日本上市!


  • 如您发现本网站有文字编辑或内容错误,请点击此处发送(需要安装有foxmail或outlook支持),


    或发邮件至:info@morecare.hk,香港济民药业感谢您的到访!


    欢迎您添加香港济民药业微信,或在公众号内留言。

    香港济民微信公众号
    • 香港济民药业友情链接
    • 友情链接

    联系我们:

    地址:
    Rm. 314, Sun Ling Plaza, 30 On Kui Street, Fanling, HONG KONG
    邮箱:
    info@pidrug.com
    电话:
    198 9654 1773
    粤ICP备17150936号
    香港济民药业官方网站
    • 关注我们 :
    • 香港济民药业微博
    • 关注香港济民药业博客
    • 香港济民药业微信公众号